(HealthDay)—Teprotumumab is associated with better outcomes than placebo among patients with active thyroid eye disease, according to a study published
Home »
ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 — For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is